What is Zacks Research's Estimate for PBH Q3 Earnings?

Key Points

• Zacks Research has lowered its Q3 2026 earnings per share (EPS) estimate for Prestige Consumer Healthcare to $1.20, down from $1.21, while maintaining a "Strong Sell" rating on the stock.
• The consensus estimate for the company's full-year earnings remains at $4.50 per share, with quarterly projections for Q4 2026 set at $1.37 EPS.
• Institutional investors currently hold 99.95% of Prestige Consumer Healthcare's shares, reflecting strong institutional interest in the company amidst recent trading activity.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Investment analysts at Zacks Research decreased their Q3 2026 EPS estimates for Prestige Consumer Healthcare in a research note issued to investors on Thursday, October 16th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.20 for the quarter, down from their previous estimate of $1.21. Zacks Research currently has a "Strong Sell" rating on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q4 2026 earnings at $1.37 EPS, FY2026 earnings at $4.50 EPS, Q4 2027 earnings at $1.25 EPS and FY2027 earnings at $4.81 EPS.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings reiterated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Sidoti raised shares of Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 target price for the company in a report on Wednesday, September 24th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Prestige Consumer Healthcare has a consensus rating of "Hold" and a consensus target price of $94.80.

Prestige Consumer Healthcare Trading Up 1.4%

NYSE PBH opened at $61.78 on Friday. Prestige Consumer Healthcare has a 12 month low of $60.15 and a 12 month high of $90.04. The stock has a market cap of $3.04 billion, a P/E ratio of 14.50, a P/E/G ratio of 1.93 and a beta of 0.44. The stock's fifty day moving average price is $64.38 and its 200-day moving average price is $75.54. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). The company had revenue of $249.53 million during the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business's quarterly revenue was down 6.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kayne Anderson Rudnick Investment Management LLC grew its position in Prestige Consumer Healthcare by 45.3% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company's stock worth $135,903,000 after purchasing an additional 493,199 shares during the period. Geode Capital Management LLC boosted its stake in shares of Prestige Consumer Healthcare by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company's stock worth $112,843,000 after buying an additional 9,455 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Prestige Consumer Healthcare by 24.7% in the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock worth $113,635,000 after acquiring an additional 261,537 shares during the period. Congress Asset Management Co. increased its position in Prestige Consumer Healthcare by 1.8% during the second quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company's stock valued at $80,616,000 after acquiring an additional 18,015 shares during the last quarter. Finally, Westwood Holdings Group Inc. lifted its holdings in Prestige Consumer Healthcare by 2.4% in the second quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company's stock valued at $70,420,000 after acquiring an additional 20,626 shares during the period. Institutional investors own 99.95% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.